Ladenburg lowered the firm’s price target on Beyond Air (XAIR) to $2 from $4 and keeps a Buy rating on the shares after fiscal Q2 revenues of $0.8M were in-line with the firm’s estimate of $0.9M. The cardiac PMA supplement is accepted and under review, while the LungFit PH CE mark decision is expected by year-end 2024, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR: